News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Techulon, Inc. Awarded $1.9 Million to Defeat "Superbugs"



5/9/2013 10:55:48 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BLACKSBURG, Va.--(BUSINESS WIRE)--Techulon, Inc. announced today that it has been selected by the Defense Advanced Research Projects Agency (DARPA) for a Phase II contract to advance its therapeutic program for multi-drug resistant bacteria, or ‘superbugs.’ This award drives Techulon’s development of a nanotherapeutic agent that will give the Department of Defense and hospitals the ability to rapidly respond and treat patients with life-threatening multi-drug resistant infections. Techulon successfully completed an early feasibility program of its technology platform in 2012 with DARPA leading up to the current award.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES